Investors

2024 full year and fourth quarter announcement

We announced our full year and fourth quarter 2024 results on Wednesday 5 February. Access our full year and fourth quarter results and latest Annual Report below.

FY 2024 results Annual Report 2024

Close Video

We’re confident in our future

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Why invest in GSK?

01 / 05

Previous slide Next slide

Goldman Sachs Biopharma Innovation Summit

Access all speeches and presentations

27 March 2025

David Redfern, President, Corporate Development, attended the Goldman Sachs Biopharma Innovation Summit in London on Thursday, 27 March 2025.

BNP Paribas Exane Healthcare Conference

Access all speeches and presentations

25 March 2025

Julie Brown, Chief Financial Officer, participated in a virtual fireside chat at the BNP Paribas Exane Healthcare Conference on Tuesday, 25 March 2025.

TD Cowen 45th Annual Health Care Conference

Access all speeches and presentations

03 March 2025

Luke Miels, Chief Commercial Officer, participated in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on Monday, 3 March 2025.

43rd Annual J.P. Morgan Healthcare Conference

Listen to the webcast

14 January 2025

Emma Walmsley, Chief Executive Officer, presented at the 43rd annual JP Morgan Healthcare Conference on Tuesday 14 January. The 40 minute session included a presentation and a moderated Q&A discussion.

Meet the management: Early pipeline

Watch the recording

17 December 2024

On 17 December, GSK management held a virtual event, "Early pipeline", featuring a presentation and an interactive Q&A session.

Shareholder information

GSK dividend

GSK share price

Share price tool

Detailed information on GSK's share price, including an interactive chart

Go to share price tool

Behind the science

Read our latest articles

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

‘Long-acting therapies are no longer the future of HIV treatment – they are the now’

Is it COVID-19, flu, or RSV? The symptoms to look out for – and how to tell the difference

‘The whooping cough outbreak is a stark reminder of just how important lifelong vaccination is’

‘It was not something I was warned about’: Preventing permanent organ damage in patients with lupus

78% of gynaecologic cancer patients experience challenges accessing the treatment they need, new survey shows

'Prevention is the best medicine to stop disease before it starts'

Behind the science magazine

Continue to Media

Investors

2024 full year and fourth quarter announcement

We’re confident in our future

Speeches and presentations

Goldman Sachs Biopharma Innovation Summit

BNP Paribas Exane Healthcare Conference

TD Cowen 45th Annual Health Care Conference

43rd Annual J.P. Morgan Healthcare Conference

Meet the management: Early pipeline

Shareholder information

GSK dividend

GSK share price

Share price tool

Read our latest articles

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

‘Long-acting therapies are no longer the future of HIV treatment – they are the now’

Is it COVID-19, flu, or RSV? The symptoms to look out for – and how to tell the difference

‘The whooping cough outbreak is a stark reminder of just how important lifelong vaccination is’

‘It was not something I was warned about’: Preventing permanent organ damage in patients with lupus

78% of gynaecologic cancer patients experience challenges accessing the treatment they need, new survey shows

'Prevention is the best medicine to stop disease before it starts'

You might also like

Investors

2024 full year and fourth quarter announcement

We’re confident in our future

Stock exchange announcements

Quarterly results

Analyst consensus

Financial reports

Speeches and presentations

Goldman Sachs Biopharma Innovation Summit

BNP Paribas Exane Healthcare Conference

TD Cowen 45th Annual Health Care Conference

43rd Annual J.P. Morgan Healthcare Conference

Meet the management: Early pipeline

Shareholder information

GSK dividend

Dividend calculators (GBp/USD)

Dividend calendar

GSK share price

London

Share price at 07 April 2025 08:44

NYSE

Share price at 04 April 2025 16:00

Share price tool

Read our latest articles

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

‘Long-acting therapies are no longer the future of HIV treatment – they are the now’

Is it COVID-19, flu, or RSV? The symptoms to look out for – and how to tell the difference

‘The whooping cough outbreak is a stark reminder of just how important lifelong vaccination is’

‘It was not something I was warned about’: Preventing permanent organ damage in patients with lupus

78% of gynaecologic cancer patients experience challenges accessing the treatment they need, new survey shows

'Prevention is the best medicine to stop disease before it starts'

You might also like

Pipeline

Our leading scientists

Governance